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Pandemic infection or reemergence of Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) occurs in tropical and subtropical
regions, being associated with hand-foot-and-mouth disease, herpangina, aseptic meningitis, brain stem encephalitis, pulmonary
edema, and paralysis. However, eﬀective therapeutic drugs against EV71 and CVA16 are rare. Kalanchoe gracilis (L.) DC is used
for the treatment of injuries, pain, and inﬂammation. This study investigated antiviral eﬀects of K. gracilis leaf extract on EV71
and CVA16 replications. HPLC analysis with a C-18 reverse phase column showed ﬁngerprint proﬁles of K. gracilis leaf extract
had 15 chromatographic peaks. UV/vis absorption spectra revealed peaks 5, 12, and 15 as ferulic acid, quercetin, and kaempferol,
respectively. K. gracilis leaf extract showed little cytotoxicity, but exhibited concentration-dependent antiviral activities including
cytopathic eﬀect, plaque, and virus yield reductions. K. gracilis leaf extract was shown to be more potent in antiviral activity than
ferulic acid, quercetin, and kaempferol, signiﬁcantly inhibiting in vitro replication of EV71 (IC50 = 35.88μg/mL) and CVA16
(IC50 = 42.91μg/mL). Moreover, K. gracilis leaf extract is a safe antienteroviral agent with the inactivation of viral 2A protease and
reduction of IL-6 and RANTES expressions.
1.Introduction
Kalanchoe gracilis (L.) DC, “Da-Huan-Hun” in Chinese, is
a traditional Chinese medicinal herb belonging to the Cras-
sulaceae family, a folk medicine commonly used for treating
injuries, pain, fever, and inﬂammation in Taiwan [1, 2].
Extracts of K. gracilis have high amounts of polyphenol and
ﬂavonoid contents that may generate potential antioxidant,
anti-inﬂammatory, and antiproliferative activities [2, 3].
Identiﬁed constituents include coumarin, bufadienolides,
ﬂavonoids(e.g.,teolin,quercetin,quercitrin,kaempferoland
eupafolin), and glycosidic derivatives of eupafolin [4, 5]. The
latter is a vital bioactive compound shown to possess antiox-
idant and anti-inﬂammatory eﬀects in lipopolysaccahride-
treated RAW264.7 cells as well as antiproliferating eﬀect
against HepG2 cells [3]. Coumarin-based compounds are
reported with antiviral activities against Hepatitis C and
human immunodeﬁciency virus 1 (HIV-1) [6–10]. 3-Phenyl
coumarin-based compounds were previously reported to
bind with viral protein R (Vpr) and inhibit Vpr-dependent
HIV replication in human macrophages [10]. Chiang et al.
[7] also proved less than 1μM of synthetic analogue of bis-
or tetra-coumarin required to inhibit HIV-1 integrate by
half. Flavonoids are reported to hold a broad spectrum of2 Evidence-Based Complementary and Alternative Medicine
antiviral activity eﬃciently inhibiting replication of human
rhinovirus, Sabin type 2 polio, Hepatitis A, coxsackievirus
B4, and echovirus 6 [11–14]. Extract of Kalanchoe farinacea,
another species of the Crassulaceae family, has shown
antiviralactivityagainstinﬂuenzaAandherpessimplexvirus
Type 1 in vitro [15]. Bufadienolides identiﬁed from leaves
of two other Crassulaceae plants, Kalanchoe pinnata and K.
daigremontiana x tubiﬂora, inhibit activation of Epstein-Barr
virus early antigen in Raji cells [16]. Together with antiviral
dataofrelatedcompoundsandCrassulaceaeplants,K.gracilis
oﬀers a valuable source of antiviral agents.
Enteroviruses (EVs) are members of the Picornaviridae
family, which have in common a 7.4kb single-stranded
positive-sense RNA genome [17]. Enterovirus genome en-
codesasinglelargepolyproteincleavedbyenteroviral2Aand
3C proteases. After protein synthesis, viral polyproteins are
cleaved into four capsid (VP1 to VP4) and seven nonstruc-
turalproteins(2A,2B,2C,3A,3B,3C,and3D).Manycrucial
pathogens are enteroviruses: for example, polioviruses, cox-
sackievirus A (CVA) and B (CVB), echovirus EV68, EV69,
EV70, EV71. CVA and EV71 are independent aetiological
agentsofhand-foot-and-mouthdisease(HFMD),myocardi-
tis, ocular conjunctivitis, herpangina, aseptic meningitis, or
severe neurological complications, such as encephalitis and
poliomyelitis-like paralysis [18]. Particularly, EV71-induced
brainstem encephalitis has poor prognosis with high mor-
tality [19] ;E V 7 1o u t b r e a k sh a v eb e e nr e p o r t e di nc o u n t r i e s
in the Western Paciﬁc, Sweden, and Australia [19–22]. Such
epidemics in Taiwan caused 78 deaths in 1998 [23–26], 25
deaths in 2000, and 26 deaths in 2001 [21]. Importantly,
cocirculations of EV71 and CVA appear in serious HFMD
outbreaks in China, Taiwan, and Malaysia [26–28]. In
Taiwan, coxsackievirus A16 (CVA16) is a major serotype
of CVA isolates identiﬁed in HFMD outbreaks [26, 28].
Global poliovirus vaccination program plans to eradicate
poliovirus diseases like severe poliomyelitis worldwide; yet
no antiviral drug has been approved by FDA for treatment of
EV infection. Strategy to prevent or treat EV infection proves
essential, especially for EV71 and CVA16.
This study investigated in vitro antiviral activity of K.
gracilis leaf extract against EV71 and CVA16, using in vitro
models in pretreatment before virus adsorption, simultane-
ous treatment during infection and posttreatment after virus
adsorption. All showed signiﬁcantly less viral replication
in vitro; treatment at early and late stages showed potent
inhibition.Thisstudyalsoexaminedpossibleantiviralmech-
anisms: for example, inhibition of in vitro and cell-based 2A
protease activity, anti-inﬂammatory eﬀect on expression of
virus-induced inﬂammatory genes, activation of p38 MAPK,
ERK1/2, and NF-κB signaling pathways.
2.MaterialsandMethods
2.1. Viruses and Cells. EV71 and CVA16 were obtained from
clinical isolates in the Clinical Virology Laboratory, China
Medical University Hospital at Taichung, Taiwan. RD cells
(ATCC accession no. CCL-136) were grown in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM; Gibco) with 10% fetal
bovine serum (FBS; Gibco). All media were supplemented
with 100U/mL of penicillin and streptomycin and 2mM of
l-glutamine. HeLa-G2AwtR cells were derived from HeLa
cells containing pG2AwtR plasmid that encodes an FRET
probe as well as the fusion protein of red ﬂuorescent protein
(DsRed)—2Apro cleavage motif—green ﬂuorescent protein
(GFP) as described by Tsai et al. [29]. Cells were cultured in
Modiﬁed Eagle’s Medium (MEM; Gibco) with 10% FBS and
20μg/mL zeocin.
2.2. Preparation of K. gracilis Leaf Juice Extract. K. gracilis
was collected from farmlands and gardens in Chiayi County,
Taiwan as described in Flora of Taiwan and identiﬁed by
ProfessorHsin-FuYenfromtheNationalMuseumofNatural
Science at Taichung, Taiwan. Fresh K. gracilis leaves were
cold-pressed, resulting leaf juice ﬁltered through Whatman
No. 1 paper, then lyophilized in a freeze dryer (IWAKI FDR-
50P). This powder of leaf juice extract was stored in sterile
bottles and kept in −20◦Cf r e e z e r .
2.3. Fingerprint Analysis by HPLC. For analyzing HPLC
ﬁngerprint proﬁles, ﬁltered extract of K. gracilis leaf of ethyl
acetate layer or the marker mixture of ferulic acid, quercetin,
and kaempferol (10μL) was injected directly into the HPLC
instrument (Shimadzu LC-10A) with a C-18 reverse phase
column. Ferulic acid was purchased from Sigma-Aldrich
Chemical Co (St. Louis, Mo, USA). Quercetin was purchased
from Alfa Aesar-A Johnson Matthey Company. Kaempferol
was purchased from Extrasynthese (France). Separation was
conducted with a gradient elution of 0.25% formic acid and
acetonitrile (40% between 0 and 9min, 40–60% between 9
and 30min) at a ﬂow rate of 0.8mL/min. Chromatographic
peaks were detected at 260/360nm with a 2996 PDA
detector.
2.4. Cell Viability Assay. For cell viability, RD cells were
cultured overnight on 96-well plates. Medium containing
0, 1, 50, 250, 500, or 1000μg/mL of K. gracilis leaf extract
was added and incubated for 24 and 48 hours, followed
by MTT assay. Survival rates of cells were calculated as the
ratio of optical density at 570–630nm (OD570–630)o ft r e a t e d
cells to OD570–630 of untreated cells. Quintuplicate wells were
analyzed for each concentration. The data represented the
means ± SD of three independent experiments. Cytotoxic
concentration of 50% toxic eﬀect (CC50) was determined
using a computer program (provided by John Spouge,
National Center for Biotechnology Information, National
Institutes of Health). Ferulic acid, quercetin, and kaempferol
at concentrations of 1, 10, 50, 100, and 500μg/mL were also
tested for cytotoxicity.
2.5. Cytopathic Eﬀect (CPE) Reduction Assay. RD cells (4 ×
105 RD cells per well) were seeded to the 6-well plate. Next
day, EV71 or CVA16 at the multiplicity of infection (MOI)
of 1 was mixed with Dulbecco’s modiﬁed Eagle’s medium
containing 2% FBS alone or medium with 100μg/mL of K.
gracilis leaf extract before adding to the RD cells to incubate
for 24 and 48h at 37◦C. Cell morphology was observed and
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2.6. Plaque Reduction Assay. RD cells (4 × 105 RD cells per
well) were seeded to the 6-well plates. Next day, cells were
infected with EV71 or CVA16 (100pfu) in the absence or
presence of K. gracilis leaf extract at 10, 50, or 100μg/mL
or the marker compound (quercetin, ferulic acid, and
kaempferol) at 0.1, 1, 10, and 50μg/mL 1h at 37◦C. Then,
2mL of medium containing 3% agarose was overlaid onto
thecellsandincubatedfor2days at37◦CinaCO 2 incubator.
At the end of incubation, cells were stained with 0.1%
Crystal Violet. Ferulic acid, quercetin, and kaempferol at the
concentrations of 0.1, 1, 10, and 50μg/mL were also tested
for plaque reduction. The concentrations that reduced the
numberofplaquesby50%(IC50)werethendetermined.The
therapeutic index (TI) was determined by the ratio of CC50
to IC50.
2.7. Virucidal Activity Assay. EV71 or CVA16 (104 pfu) was
mixed with test compounds of various concentrations (0,
50, and 100μg/mL) or medium and incubated for 30min at
room temperature, then serial dilutions of the mixture were
performed using the plaque assay. The residual infectivity
was measured as described in the plaque assay.
2.8. Virus Yield and Time-of-Addition Assays. K. gracilis leaf
extract was added to RD cells before (30 min pretreatment),
during (simultaneous treatment), and after (30 min post-
treatment) the viral infections of EV71 and CVA16 at the
titer of 300pfu. 48h after infection, culture media were
collected and RNA genomes were extracted by QIAamp Viral
RNA Mini Kit (Qiagen). Real-time RT-PCR was performed
with speciﬁc primers, SYBR green PCR Master Mix, and
SYBR green I dsDNA binding dye. Oligonucleotides for VP1
were forward primer 5 -GGCCCCTGAATGCGGCTAATCC-
3  (nt 458–480) and reverse primer 5 -GCGATTGTCACC-
ATWAGCAGYCA-3  (nt603–581)asdescribedinthereport
of Oberste et al. [30]. PCR product level was monitored with
an ABI PRISM 7000 sequence detection system (Applied
Biosystems). For comparing the viral RNA load in the
culturedmedia,adeltaCtvaluewascalculatedbysubtracting
theCtvalueforviralloadinculturedmediaofK.gracilisleaf-
extract-treated infected cells from the Ct value for viral load
in cultured media of infected cells without treatment. If the
delta Ct value was greater than 3.3, indicating 50μg/mL of K.
gracilis leaf extract had more than 1-log reduction (equal to
90% eﬀective concentration [EC90]) in virus RNA loads.
2.9. Fluorescence Resonance Energy Transfer (FRET) Assay.
HeLa-G2AwtR cells (1 × 106 cells per well) expressing the
FRET probe were seeded to the 6-well tissue culture plates
and infected with EV71 or CVA16 (1 × 106 pfu). After
1h of adsorption, the inoculum was aspirated and 200μL
of modiﬁed Eagle’s medium containing 2% FBS alone or
medium with 1, 10, 50, 100, or 150μg/mL of K. gracilis
leaf extract was added to each well. Cells were harvested
48h after infection, and lysates were transferred to 96-
well plates for ﬂuorescence. The ﬂuorescent intensity of the
FRET probes was measured by a ﬂuorescent-plate reader
with an excitation wavelength at 390/20nm (for GFP2 at
510/10nm) and an emission wavelength at 590/14nm (for
DsRed2), in which DsRed2 was excited by the emission of
GFP2 at 510/10nm. The data presented are mean values of
three independent experiments, and the error bars represent
standard deviations.
2.10. Construction, Expression, and Puriﬁcation of
EV71 2A Protease. The gene encoding EV71 2A
protease was ampliﬁed using PCR with cDNA of
EV71 isolate CMUH01. The forward primer 5 -
GCGCGGATCCGGGAAATTCGGTCAGCAG-3  and the
reverse primer 5 -GCGCCTCGAGCTGCTCCATCGCTTCC
TC-3  , which contain BamHI and XhoI restriction enzyme
sites (underlined), were used for C-terminal His-tagged
protease. PCR products were digested with BamHI and
XhoI, and the DNA fragment was cloned into pET24a
(Novagen). The plasmid containing the protease gene was
subsequently transformed into E. coli Origami B (DE3)
(Novagen) for protein expression. A 10mL overnight culture
of a single colony was used to inoculate 400mL of fresh
LB medium containing 25μg/mL kanamycin. Cells were
grown to an A600 of 0.6 and induced with 1mM IPTG.
After IPTG induction overnight, cells were harvested by
centrifugationat6000rpmfor30min,andthenresuspended
in a denaturing buﬀer (10mM imidazole, 8M urea and
1mM β-mercaptoethanol) before subjecting to sonication.
Separation of the supernatant was conducted in Ni-NTA
column, and His-tagged 2A protease was allowed to renature
slowly by gradient washing with refolding buﬀer (10mM
imidazole and 1mM β-mercaptoethanol) overnight. Finally,
recombinant 2A protease was eluted with 25mM Tris-
HCl, pH 7.5, 150mM NaCl, and 300mM imidazole. The
concentration of puriﬁed protein was determined using
Bio-Rad protein assay.
2.11. In Vitro 2A Protease Activity Assay. In the protease
activity assay, 2A protease was designed to interact with
horseradish peroxidase (HRP). HRP is a commercially
available substrate, and its Leu-Gly pairs at residues 122-
123 correspond to the cleavage site by 2A protease. To
examine the most suitable concentration of 2A protease for
interactionwithHRP,2Aproteasesofvariousconcentrations
ranging from 1μg/mL to 150μg/mL were each added and
incubated with 1μg/mL of HRP for 2h at 37◦C. Mixtures
were then developed with ABTS/H2O2 and measured at
OD405. The extract of K. gracilis leaf was tested for anti-EV71
2Aproteaseactivity,thusitwasincubatedwithHRPfor2hat
37◦Cin96-wellplatesinvitro.TheremainingactivityofHRP
in each reaction was determined with a chromogenic sub-
strate ABTS/H2O2 and the intensity of the developed color
was measured at 405nm. Percentage of inhibition of EV71
2Aproteaseactivitywascalculatedbythefollowingequation:
(OD405HRP+drug+2Apro − OD405HRP+2Apro)/(OD405HRP only −
OD405HRP+2Apro) ×100%.
2.12. Quantiﬁcation of Proinﬂammatory Gene Expression
Using Real-Time RT-PCR. Total RNA was isolated from RD
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andwithorwithoutvirusinfectionviapuriﬁcationkit(Pure-
Link Micro-to-Midi total RNA Puriﬁcation System, Invitro-
gen). cDNA was synthesized from 1000ng total RNA with
oligo dT primer and SuperScript III reverse transcriptase kit
(Invitrogen). To gauge expression in response to treatment
of K. gracilis leaf extract and/or virus infection, a two-
step RT-PCR using SYBR Green I was used. The following
oligonucleotide primer pairs were used in the present study
for the detection of cytokines, including (1) forward primer
5 -TCCCCATATTCCTCGGAC-3  and reverse primer 5 -
GATGTACTCCCGAACCCA-3  for human RANTES, (2)
forward primer 5 -ATGCCCCAAGCTGAGAACCAAGAC-
CCA-3  and reverse primer 5 -TCTCAAGGGGCTGGG-
TCAGCTATCCCA-3  for human IL-10, (3) forward primer
5 -GATGGATGCTTCCAATCTGGAT-3  and reverse primer
5 -AGTTCTCCATAGAGAACAACATA-3  for human IL-6,
(4) forward primer 5 -CTCTAGAGCACCATGCTACAGAC-
3  and reverse primer 5 -TGGAATCCAGGGGAAACACTG-
3  for human IL-1α,a n d( 5 )f o r w a r dp r i m e r5  -CAT-
GCGTTTCCGTTACAAGTGCGA-3  and reverse primer
5 -TGGGTGCGTCTTAGTGGTATCTGT-3  for human NF-
κB. In addition, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA, a housekeeping gene, was measured
using 5 -AGCCACATCGCTCAGACAC-3  and 5 -GCCCCA
ATACGACCAAATCC-3  as forward and reverse primers.
Real-time PCR reaction mixture contained 2.5μL of cDNA
(reverse transcription mixture), 200nM of each primer in
SYBR Green I master mix (LightCycler TaqMAn Master,
Roche Diagnostics). PCR was performed by an ampliﬁcation
protocol consisting of 1 cycle at 50◦C for 2min, 1 cycle
at 95◦C for 10min, 40 cycles at 95◦C for 15sec, and 60◦C
for 1min. Speciﬁc products were ampliﬁed and detected in
ABI PRISM 7700 sequence detection system (PE Applied
Biosystems), and relative changes in mRNA levels of indi-
cated genes were gene normalized by housekeeping gene
GAPDH.
2.13. Western Blot Analysis. RD cells were infected with
the virus (8 × 105 pfu) in the presence or absence of K.
gracilis leaf extract. The lysate proteins of RD cells were
dissolved in 2x SDS-PAGE sample buﬀer without 2-mer-
captoethanol, boiled for 10min, and then separated on 8%
SDS-PAGE gels before being transferred to nitrocellulose
paper. Resultant blots were blocked with 5% skim milk then
reacted with properly diluted monoclonal antibodies includ-
ing anti-ERK1/2, anti-phospho-ERK1/2, anti-p38 MAPK,
anti-phospho-p38MAPK,anti-p65,anti-phospho-p65,anti-
caspase 9 (Cell Signaling Technology) and anti-β-actin.
The immune complexes were detected using horseradish
peroxidase-conjugated goat anti-mouse IgG antibodies fol-
lowed by enhanced chemiluminescence reaction (Amersham
Pharmacia Biotech).
2.14. In Vivo Anti-EV71 Assay. Suckling mice of 1-day-old
were intraperitoneally inoculated with EV71 (1.7 × 105 pfu)
and intraperitoneally injected with K. gracilis leaf extract (0,
1, 2mg/kg) once on day 1, 3, 5, 7 after-infection. 3 mice from
each group were sacriﬁced on day 2, 4, 6, and 8. Intestine
sampleswerecollectedfordetectionofvirusloadsusingreal-
time RT PCR.
2.15. Statistical Analysis. ANOVA analysis using SPSS pro-
gram (version 10.1, SPSS Inc., IL, USA) or Scheﬀet e s tw a s
used to analyze all data. P value less than 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Fingerprint Proﬁling of K. gracilis Leaf Extract. To
determine the ﬁngerprint of K. gracilis leaf extract, the ethyl
acetate layer of ﬁltered leaf extract and marker components
of ferulic acid, quercetin, and kaempferol as well were
analyzed using HPLC with a C-18 reverse phase column
(Figure 1). The retention time was found at 5.74min for
ferulic acid, 12.13min for quercetin, and 20.44min for
kaempferol at 360nm (Figure 1(a)). HPLC chromatographic
peaks of K. gracilis leaf extract of ethyl acetate layer indicated
the retention times of peaks 5, 12, and 15 were identical to
those of ferulic acid, quercetin, and kaempferol, repectively
(Figure 1(b)). UV absorption spectra (200–360nm) of peaks
5, 12, and 15 were identical as compared to the marker
components of ferulic acid, quercetin, and kaempferol,
respectively(Figure 1(c)).HPLCandUVabsorptionanalyses
revealed ﬁngerprint proﬁling as well as the maker compo-
nents in K. gracilis leaf extract.
3.2. Cytotoxicity of K. gracilis Leaf Extract in RD Cells. To
evaluate the cytotoxicity of K. gracilis leaf extract, RD cells
were treated with K. gracilis leaf extract at the concentration
range of 1–1000μg/mL. In vitro cytotoxicity assay showed
that K. gracilis leaf extract was not cytotoxic to RD cells
in the concentration range of 1–500μg/mL 24 and 48h
posttreatment (Figure 2). 50% cytotoxicity concentrations
(CC50) of ferulic acid, quercetin, and kaempferol were all
greater than 500μg/mL, and so was that of K. gracilis leaf
extract (data not shown). The results also demonstrated K.
gracilis leaf extract as being less cytotoxic in comparison with
the 3 marker components.
3.3. Inhibitory Eﬀect of K. gracilis Leaf Extract on the Replica-
tion of EV71 and CVA16. The anti-viral eﬀects of K. gracilis
leaf extract against EV71 and CVA16 were further evaluated
in virucidal activity, cytopathic eﬀect (CPE) reduction, viral
plaque reduction, and virus yield reduction assays (see
supplemental Figure 1 in Supplementary Material available
online at doi:10.1155/2012/503165, Figures 3 and 4). In
vitro incubation with 100μg/mL of K. gracilis leaf extract
for 30min at room temperature had no signiﬁcant eﬀect
on EV71 or CVA16 infectivity, indicating K. gracilis leaf
extract had no virucidal activity against EV71 and CVA16
(data not shown). However, when K. gracilis leaf extract was
added to EV71- and CVA16-infected RD cells, signiﬁcant
inhibition on EV71- and CVA16-induced CPE was observed,
as shown in Supplemental Figures 1(a) and 1(b). ForEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: HPLC ﬁngerprint proﬁles and UV/vis absorption spectra of K. gracilis leaf extract of ethyl acetate layer and marker components.
Marker components of ferulic acid, quercetin, and kaempferol (a) and K. gracilis leaf extract of ethyl acetate layer (b) were analyzed using
HPLC with a C-18 reverse phase column. Eluents were detected at 360nm. Maximum absorption wavelengths of ferulic acid, quercetin,
kaempferol, and chromatographic peaks 5, 12, and 15 were measured by UV/vis absorption spectra (200–360nm).
detection of virus yields in RD cells, the culture supernatants
of EV71- and CVA16-infected RD cells with and without
simultaneous-treatment of K. gracilis leaf extract in the
concentration range of 1–200μg/mL were harvested on day
2 and analyzed for viral RNA loads, using quantitative real-
time RT-PCR (Figure 3). Real-time RT-PCR assay indicated
that viral RNA loads in the supernatant of infected cells
treated with 50μg/mL of K. gracilis leaf extract (a Ct value
of 31.68 for EV71 and a Ct value of 28.20 for CVA16) were
signiﬁcantly lower than those of infected cells without K.
gracilis leaf extract treatment (a Ct value of 13.82 for EV71
and a Ct value of 14.25 for CVA16) (Figure 3). Moreover,
treatment with K. gracilis leaf extract at 50μg/mL had more
than 1-log reduction in virus RNA loads since its delta
Ct value was greater than 3.3. In addition, K. gracilis leaf
extract exhibited concentration-dependent inhibitory eﬀects
on the replication of EV71 and CVA16 using plaque assay
(Figure 4). IC50 value of K. gracilis leaf extract in plaque
reduction assay was 35.88μg/mL for EV71 and 42.91μg/mL
for CVA16. Moreover, quercetin, but not ferulic acid and
kaempferol, showed a concentration-dependent manner on
plaque reduction (IC50 = 39.63μg/mL for EV71; IC50 =
59.53μg/mL for CVA16) (Figure 5). The therapeutic index
(TI) of K. gracilis leaf extract was greater than 10 against
EV71 and CVA16, while quercetin TI was less than 10 against
CVA16. K. gracilis leaf extract demonstrated higher antiviral
potential than its marker component quercetin in treatment
of EV71 and CVA16 infections.6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Cytotoxicity of K. gracilis leaf extract. RD cells were
cultured overnight on 96-well plates. Serial dilutions of K. gracilis
leaf extract were added and incubated for 24 and 48 hours, followed
by MTT assay. Survival rates of cells were calculated as the ratio
of optical density at 570–630nm (OD570–630) of treated cells to
OD570–630 ofuntreatedcells. ∗P value<0.05; ∗∗P value<0.01; ∗∗∗P
value < 0.001 by Scheﬀe’s test.
3.4. Antiviral Eﬀect in Diﬀerent Stages of EV71 and CVA16
Infections. To examine the possible mechanisms of K. gracilis
leaf extract against EV71 and CVA16, the antiviral activity
of K. gracilis leaf extract was further determined using time
of addition studies (Figure 6). RD cells were treated with
50μg/mL of K. gracilis leaf extract 30min before, during,
and 30min after infection. Viral RNA quantitative real-
time PCR demonstrated that K. gracilis leaf extract reached
90% yield reduction of EV71 at 12h by the post-treatment
procedureandat36hbythepre-treatmentandsimultaneous
treatment procedures (Figure 6(a)). In addition, pre- and
post-treatments of K. gracilis leaf extract both exerted 90%
reductions in the yield of CVA16 at 24h, and simultaneous-
treatmentofK.gracilisleafextractachieved90%reductionat
36h (Figure 6(b)). The results showed antiviral eﬀects of K.
gracilis leaf extract on EV71 and CVA16 replications, being
possibly associated with targeting viral protein function,
reducing virus-induced cytopathogenesis, or inducing host
antiviral responses.
3.5.InhibitionofViral2AProteaseActivityinCell-BasedFRET
by K. gracilis Leaf Extract. Since enterovirus 2A protease
that cleaves viral polyproteins and cellular factors has mul-
tifaceted activities for regulating diﬀerent viral and cellular
processes including viral replication and cytopathogenesis,
particular in apoptosis and innate immunity [31], the
possible inhibitory mechanisms of K. gracilis leaf extract on
viral 2A protease was tested using a cell-based FRET assay
of viral 2A protease activity. In general, a stable cell line
continuously expressing GFP2-DsRed2 fusion protein con-
nected by 2A protease cleavage site was used (HeLa-G2AwtR
cells; GRTTLSTR↓GPPRGGPG; ↓ indicates cleavage site).
The fusion protein would be cleaved by viral 2A protease
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Figure 3: Reduction of virus yields by K. gracilis leaf extract. Each
virus at the titer of 300pfu was mixed with K. gracilis leaf extract
and then added into RD cell cultures. Virus titers in each cultured
supernatant were measured 48 h after infection using real-time RT-
PCR. The delta Ct value was calculated by subtracting the Ct value
for viral load in cultured media of K. gracilis leaf-extract-treated
infected cells from the Ct value for viral load in cultured media of
infected cells without treatment. Assay was performed as described
in the Section 2. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value <
0.001 by Scheﬀet e s t .
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Figure 4: Plaque reduction of K. gracilis leaf extract. RD cells
were infected with EV71 or CVA16 at a titer of 100pfu and
simultaneously treated with K. gracilis l e a fe x t r a c ta tc o n c e n t r a t i o n s
of 0, 10, 50, and 100μg/mL. After 1h incubation, RD cells were
covered with agarose overlay medium and incubated for 2 days at
37◦Ci naC O 2 incubator. Finally, the cells were stained with 0.1%
crystal violet. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value < 0.001
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Figure 5: Plaque reduction of quercetin, ferulic acid and kaempferol. RD cells were infected with EV71 (a) or CVA16 (b) at a titer of 100pfu
and simultaneously treated with quercetin, ferulic acid, and kaempferol at concentrations of 0, 0.1, 1, 10, and 50μg/mL. After 1h incubation,
RD cells were covered with agarose overlay medium and incubated for 2 days at 37◦Ci naC O 2 incubator. Finally, the cells were stained with
0.1% crystal violet. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value < 0.001 by Scheﬀet e s t .
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Figure 6: Time of addition assay for analysis of inhibitory eﬀects of K. gracilis leaf extract on viral replication processes. K. gracilis leaf
extracts at concentrations of 0 and 50μg/mL were added to RD cells before (pre-treatment), during (simultaneous treatment), and after
(post-treatment) infection with EV71 (a) or CVA16 (b) at the titer of 300pfu. Virus titer in each cultured supernatant was measured 48h
afterinfectionusingreal-timeRT-PCR.Assaywas performedas describedin Section 2. ∗P value<0.05; ∗∗P value<0.01; ∗∗∗P value <0.001
by Scheﬀe’s test.
at time of infection. To test FRET eﬃciency, HeLa-G2AwtR
cells were infected with EV71 or CVA16 at MOIs of 0.25,
0.5, and 1 for 48h and were harvested and subjected to
measurement by a ﬂuorescent-plate reader. The FRET ratio
was deﬁned as the intensity of emission at 590/14nm for
DsRed2 divided by that of GFP2 at 510/10nm. Compared
withthemockinfectioncontrol,infectedHeLa-G2AwtRcells
exhibited a decline in percentage of the emission intensity
of FRET probes in a virus titer-dependent manner (data not
shown).
To further evaluate the inhibitory eﬀects of K. gracilis
leaf extract on the emission intensity of FRET probes in
infected cells, HeLa-G2AwtR cells were infected with EV71
or CVA16 at MOI = 1 for 48h. After 60 min of adsorption,
theinoculumwasaspiratedand200μLofmedium(modiﬁed
Eagle’s medium containing 2% FBS) alone or medium with
K. gracilis leaf extract at various concentrations was added
to each well (Figure 7). As shown in Figure 7, K. gracilis leaf
extract increased the emission intensity of FRET probes in
cells infected with EV71 and CVA16, exhibiting inhibitory8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Cell-based FRET assays for characterization of inhibitory
eﬀects of K. gracilis leaf extract on virus 2A protease enzymatic
activity. HeLa-G2AwtR cells were infected with EV71 or CVA16 at a
MOI of 1, and the cells were washed with MEM and then treated
with K. gracilis leaf extract at the dosages of 1, 10, 50, 100, and
150μg/mL. 12, 24, 36, and 48h after infection, cells were harvested
and subjected to measurement by a ﬂuorescent-plate reader with
the excitation wavelength at 390/20nm and emission wavelength
at 510/10nm (for GFP2) or 590/14nm (for DsRed2). FRET ratio
was deﬁned as intensity of emission at 590/14nm divided by that at
510/10nm. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value < 0.001
by Scheﬀet e s t .
eﬀectonenteroviral2Aproteaseactivityinadose-dependent
manner. IC50 values of K. gracilis leaf extract in cell-based
FRET assay were 40.82μg/mL for EV71 and 47.84μg/mL for
CVA16. The result implied K. gracilis leaf extract inhibited
the proteolytic activity of EV71 and CVA16 2A proteases.
3.6. Inhibition of In Vitro 2A Protease Activity by K. gracilis
Leaf Extract. To conﬁrm the inhibitory eﬀect of K. gracilis
leaf extract on viral 2A protease, in vitro cleavage assay of
recombinant 2A protease was performed using horseradish
peroxidase-based substrate. The cDNA fragment of EV71
2A protease gene was cloned into pET24a expression vector
and in-frame-fused with a C-terminal hexa-His-tag. EV71
2A protease protein was expressed in the recombinant E. coli
cells after IPTG induction and puriﬁed using immobilized-
metal aﬃnity chromatography (IMAC) (Figure 8(a)). West-
ern blot analysis of puriﬁed recombinant 2A protein with
anti-His-tag antibody revealed an immunoreactive band
near 17.3 kDa, matching closely to the expected molecular
weight (Figure 8(b)). Recombinant 2A proteases of various
concentrations (0.75, 1, 2.5, 5, and 10μg/mL) were each
added and incubated with HRP. The uncleaved HRP in
each reaction was then incubated with ABTS/H2O2 and
the remaining HRP activity measured at OD405. As shown,
OD405 exhibited a reverse dose-dependent relationship with
the increase of 2A protease (Figure 8(c)). IC50 value of K.
gracilis leaf extract in 2A protease assay was 32.46μg/mL for
EV71. Moreover, this in vitro cleavage assay of recombinant
2A protease using HRP-based enzymatic method demon-
strated K. gracilis leaf extract processed a speciﬁc inhibition
of 2A protease.
3.7. Inhibition of Virus-Induced Apoptosis and Proinﬂamma-
tory Gene Expression by K. gracilis Leaf Extract. Since 2A
protease was associated with EV71-induced apoptosis [32],
WesternblottinganalysisofEV71-infectedcellswithorwith-
out the treatment of K. gracilis leaf extract was performed
using anti-caspase 9 antibodies (Supplemental Figure 3). K.
gracilis leaf extract signiﬁcantly reduced the proform and
active form of caspase 9 in EV71-infected cells, indicating
that the inhibitory eﬀect of K. gracilis leaf extract on 2A
protease correlated with the decrease of EV71-induced apop-
tosis. Moreover, 2A protease interferes nuclear-cytoplasmic
traﬃcking of NF-κB via the cleavage of FG nucleoporins
[31]; the present study further examined whether K. gra-
cilis leaf extract inhibited virus-induced inﬂammatory gene
expression and induced signal pathways by quantitative real-
timePCRandWesternblotassay(Figure 9andSupplemental
Figure 2). Both EV71 and CVA16 causedsigniﬁcant increases
in IL-6 and RANTES mRNA levels; on the other hand, IL-10,
NF-κBp 6 5a n dI L - 1 α were not elevated in RD cells 8h after
infection (Figure 9(a)). Treatment of K. gracilis leaf extract
showed concentration-dependent inhibitions of EV71- and
CVA16-induced IL-6 and RANTES expressions (Figures
9(b) and 9(c)), indicating signiﬁcant inhibitory eﬀect on
EV71- and CVA16-induced inﬂammations. Subsequently,
phosphorylation of p38 MAPK, ERK1/2, and NF-κBp 6 5
in virus-infected RD cells with or without treatment of
K. gracilis leaf extract was analyzed by Western blotting
with phosphorylation site-speciﬁc antibodies (Supplemen-
tal Figure 2). EV71 and CVA16 infections caused time-
dependent increases of p38 MAPK, ERK1/2, and NF-κBp 6 5
phosphorylation. Treatment with K. gracilis leaf extract in
infected cells inhibited NF-κB p65 phosphorylation 4h after
infection. Results demonstrated that inhibition of EV71- and
CVA16-induced IL-6 and RANTES expressions correlated
with the reduction of NF-κB p65 activation in RD cells
and suggested that the antiapoptotic and anti-inﬂammatory
eﬀect of K. gracilis leaf extract was involved in its antiviral
activity against EV71 and CVA16.
3.8. In Vivo Antiviral Activity by K. gracilis Leaf Extract. To
evaluate in vivo antiviral activities of K. gracilis leaf extract,
viral loads were examined in intestine samples from EV71-
inoculated suckling mice with or without treatment of K.
gracilis leaf extract (Supplemental Table 1). In a suckling
mouse model, EV71 were detectable in intestine samples
on days 2, 4, and 6 after intraperitoneal inoculation. Eﬀect
of treatment with K. gracilis leaf extract in EV71 EV71-
inoculated suckling mice demonstrated an undetectable
virus load in intestine samples on day 2 by one intraperi-
toneal injection of 2mg/kg of K. gracilis leaf extract and on
day 6 by three intraperitoneal injections of 1mg/kg of K.
gracilis leaf extract. Results revealed in vivo antiviral activity
ofK.gracilisleafextractaswellasaconcentration-dependentEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: In vitro recombinant 2A protease enzymatic assay. SDS-PAGE (a) and Western blot analysis (b) of the puriﬁed 2A protease.
Recombinant 2A protease protein was expressed after induction of IPTG treatment and puriﬁed through fusion His-tag bound to Ni-NTA
agarose column. Puriﬁed recombinant 2A protease proteins were resolved on 10% SDS-PAGE and transferred onto nitrocellulose paper. The
blot was probed with anti-His-tag and developed with an alkaline phosphatase-conjugated secondary antibody and NBT/BCIP substrates.
Lane 1 represents protein molecular weight markers. Lanes 2–9 show the fractions of the puriﬁed 2A protease proteins. For characterization
of recombinant 2A protease activity in vitro (c), puriﬁed 2A protease at concentrations of 0, 0.75, 1, 2.5, 5 and 10μg/mL were incubated
with HRP (0.5μg/mL concentration) for 2h at 37◦C. Mixtures were developed with ABTS/H2O2 and measured at OD405. For inhibitory
enzymatic assays (d), K. gracilis leaf extract at concentration of 1, 10, 50, 100, or 150μg/mL was added into the mixture of puriﬁed 2A
protease and HRP then incubated for 2h at 37◦C in 96-well plates in vitro. Mixtures were developed with ABTS/H2O2 and measured at
OD405. Percentage of inhibition of 2A protease activity was calculated as (OD405HRP + drug + 2A protease−OD405HRP + 2A protease)/(OD405HRP only−
OD405HRP + 2A protease) × 100%. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value < 0.001 by Scheﬀe’s test.
manner on inhibiting EV71 replication in the intestine of
suckling mice.
4. Discussion
K. gracilis is a traditional Chinese medicinal herb commonly
used for the treatments of injury, pain, and inﬂammation;
such eﬀects have also been evidenced in animal experi-
ments of formalin-induced nociception and λ-carrageenan-
induced inﬂammation recently [2]. This study demonstrated
K. gracilis leaf extract exhibiting the antiviral activity
against EV71 and CVA16 in vitro and in vivo (Figures 3–
8, Supplemental Table 1). The results indicated K. gracilis
exhibiting antiviral eﬀects similar to other species in the
Kalanchoe genus. For example, K. pinnata Pers. has been
shown with signiﬁcant antiviral activity against Herpes
Simplex and Epstein-Barr viruses [16]. K. farinacea inhibits
in vitro replication of Inﬂuenza A and Herpes Simplex Virus
Type 1 [15]. K. brasiliensis possesses anti-inﬂammatory and
immunosuppressive eﬀects on zymosan-induced inﬂamma-
tion in mice [33]. Extracts of Kalanchoe farinacea have
in vitro antiviral activity against Inﬂuenza A and Herpes
Simplex Type 1 [15]. Together with the results and the
previous reports, herb species in the Kalanchoe genus could
possess active antiviral compounds.
HPLC and UV/vis absorption spectra demonstrated the
chemical contents and the ﬁngerprint proﬁle of K. gracilis
leaf extract of ethyl acetate layer by using a photodiode
arraydetector(Figure 1).Therelativeamountsofferulicacid
(∼7.59% w/w), quercetin (∼0.33% w/w), and kaempferol
(∼0.16% w/w) were also identiﬁed in K. gracilis leaf extract
of ethyl acetate layer and were found to be in agree-
ment with identiﬁed ﬂavonoids of K. gracilis in previous
reports [3–5]. Flavonoids exhibit multiple functions, of10 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Relative levels of pro-inﬂammatory gene expression in infected RD cells with or without the treatment of K. gracilis leaf extract.
For detection of virus-induced proinﬂammatory gene expression (a), RD cells were infected with EV71 or CVA16 for 8h then harvested
for RNA extraction. Real-time RT-PCR was performed as described in Section 2. For detection of inhibitory eﬀect of K. gracilis leaf extract
on virus-induced proinﬂammatory gene expression, EV71- or CVA16-infected cells (b, c) were simultaneously treated with K. gracilis leaf
extract at concentrations of 0, 50, and 100μg/mL. After 8h of incubation, total RNA was isolated from each group and Real-time RT-PCR
was performed as described in Section 2. ∗P value < 0.05; ∗∗P value < 0.01; ∗∗∗P value < 0.001 by Scheﬀe’s test.
which inhibition on viral replication [11–14]i sa m o n g .I n
the present study, quercetin was demonstrated to possess
concentration-dependent antienteroviral activities with the
IC50 values of 39.63μg/mL for EV71 and 59.53μg/mL
for CVA16 (Figure 5). However, anti-enteroviral activity of
quercetin was less eﬀective than that of K. gracilis leaf extract
(Figure 4). K. gracilis leaf extract is suggested to contain
other potent anti-enteroviral components besides quercetin.
Phytochemically, Kalanchoe species are known to contain
ﬂavonoids (e.g., teolin, quercetin, quercitrin, kaempferol,
eupafolin), glycosidic derivatives of eupafolin, bufadieno-
lides, and coumarins [4, 5, 16], of which bis- and tetra-
coumarins have been shown with inhibitory eﬀects on the
activity of HIV-1 integrase [7], while bufadienolides can
reducetheactivationofEpstein-Barrvirusearlyantigen[16].
In addition, many active compounds of natural products
have been identiﬁed as potential anti-EV71 agents, including
gallic acid (IC50 = 0.8μg/mL) [34], allophycocyanin (IC50 =
0.056μM)[35],chrysosplenetin(IC50 =0.2μM),penduletin
(IC50 = 0.2μM) [36], and aloe-emodin (IC50 = 0.14μM)Evidence-Based Complementary and Alternative Medicine 11
[37]. This study revealed that quercetin showed a speciﬁc
anti-EV71 activity (IC50 = 39.6μg/mL), but might be less
potent than the active compounds of natural products in
above previous reports. Therefore, active phytochemical
contents of K. gracilis leaf extract against EV71 and CVA16
should be further characterized.
In the evaluation of cytotoxicity of K. gracilis leaf
extract, it was shown that it manifested less cytotoxicity in
comparisonwithferulicacid,quercetin,andkaempferol.Not
only that, it showed better antiviral activities against EV71
and CVA16 as compared to the three marker components
(Figures 2–4, Supplemental Figure 1). K. gracilis leaf extract
at the concentration of 50μg/mL potently inhibited 90%
yield production of both viruses in RD cells (Figure 3). Also,
IC50 value of K. gracilis leaf extract against EV71 and CVA16
were 35.88μg/mL and 42.91μg/mL, respectively (Figure 4),
while the therapeutic index of K. gracilis leaf extract against
EV71 and CVA16 ranged from 23 to 28. A literature survey
indicated some extracts of Chinese herbs exhibiting anti-
EV71 activities in vitro,s u c ha sHouttuynia cordata Thunb
(IC50 = 125.9μg/mL) [38], Woodfordia fruticosa Kurz (IC50 =
1.2μg/mL) [34], Salvia miltiorrhiza (IC50 = 585μg/mL) [39],
Pueraria lobata (IC50 = 0.028μg/mL) [40], and Glycyrrhiza
uralensis (IC50 = 0.056μg/mL) [41]. Therefore, K. gracilis leaf
extract exhibited moderately potent anti- EV71 and CVA16
activities.
Although pre- and post-treatments of K. gracilis leaf
extract exhibited time diﬀerences, the two treatments
reached 90% viral reductions (Figure 6), implying that
antiviral activity of K. gracilis leaf extract could be asso-
ciated with targeting viral proteolytic enzymes, viral RNA
replication machinery, and host cell factors, and even
reducing virus-induced cytopathogenesis, or inducing host
antiviral responses. Because enterovirus 2A protease cleaves
viral polyproteins and cellular factors in which regulates
in apoptosis and nuclear-cytoplasmic traﬃcking of NF-κB
[31, 32], viral 2A protease was selected as the possible
target by K. gracilis leaf extract. In vitro recombinant 2A
protease and cell-based FRET assays indicated K. gracilis
leaf extract inhibited the enzymatic activity of viral 2A
proteases in a concentration-dependent manner (Figures
7 and 8). In addition, K. gracilis leaf extract signiﬁcantly
reduced the EV71-induced apoptosis, such as decreasing
proform and active form of caspase 9 in EV71-infected
cells (Supplemental Figure 3). Likewise, K. gracilis leaf
extract abated the up-regulation of IL-6 and RANTES gene
expressions due to EV71 and/or CVA16 infection (Figure 9)
whichcorrelatedwithdown-regulationofvirus-inducedNF-
κB-mediated signaling (Supplemental Figure 2). Therefore,
K. gracilis leaf extract exhibited an inhibitory eﬀect on
enteroviral 2A protease. This action might be in agreement
with the decrease of virus-induced apoptosis and NF-κB-
mediated proinﬂammation. Our future perspective would be
topurifyandidentifypotentK.gracilicompoundsasviral2A
inhibitors.
It has been shown that signiﬁcant increases in the
levels of IL-1β, IL-6, IL-10, IL-13, IFN-γ,a n dT N F - α are
detected in the serum and cerebral spinal ﬂuid of EV71-
infected patients [23, 42–45]. Moreover, elevation of IL-1β,
IL-6, and TNF-α in CSF strongly correlates with clinical
severity and is believed to be responsible for EV71-induced
immunopathogenesis [26, 44, 46]. Clinically, treatment of
anti-IL-6 neutralizing antibodies increases survival rates,
reduces tissue damage, and activates immune cells, but could
not aﬀect the viral loads in EV71-infected neonate mice
[47]. We demonstrated K. gracilis leaf extract concentration
dependently reduced IL-6 mRNA levels upregulated by
EV71 or CVA16 infection in RD cells (Figures 9(a)–9(c)).
Moreover, we suggested signiﬁcant inhibitory eﬀects of K.
gracilis leaf extract on in vitro replications of EV71 and
CVA16 (Supplemental Figure 1, Figures 4–6) associated with
its potent inhibition on viral 2A protease activities (Figures 7
and 8). Therefore, a combination of eﬀective compounds of
K. gracilis leaf extract shows a potential therapeutic approach
against enteroviral infection.
In conclusion, K. gracilis leaf extract contains eﬀective
compounds with anti-enteroviral activities. K. gracilis leaf
extract possesses potent eﬀects in inhibiting enzymatic activ-
ities of viral 2A protease and reducing virus-induced expres-
sion of pro-inﬂammatory cytokines IL-6 and RANTES. K.
gracilis leaf extract could be a safe and potential therapeutic
agent against enteroviral infection.
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